ERBB2 and breast carcinoma: Among HER2-negative cases (n = 261), the distribution of breast cancer phenotype on baseline biopsy according to HER2 expression was as follows: HER2-0 44.4% (n = 116), HER2-low-positive 55.6% (n = 145).